title: Usefulness of primary angioplasty in nonagenarians with acute myocardial infarction.
abstract: The optimal reperfusion strategy in very elderly patients with ST-segment elevation myocardial infarction is still a subject of debate. The aim of this multicenter study was to determine the medium-term outcomes of nonagenarians after primary percutaneous intervention for ST-segment elevation myocardial infarction. A systematic review of the databases of 7 Italian centers showed that these had performed 5,023 primary angioplasties over the previous 5 years, 100 of which (2%) involved patients > or =90 years old. Thirty-five subjects were in Killip class III or IV at time of presentation, 78 had multivessel coronary artery disease, and mean ejection fraction was 0.40 +/- 0.12%. In-hospital mortality was 19% and was significantly higher in patients with shock (58% vs 10%, p <0.001). Survival rate after 6 months was 68%: 16% in those with Killip class IV at admission and 81% in the remaining patients (p <0.001). Cox regression analysis identified 3 independent predictors of 6-month mortality: cardiogenic shock at presentation (hazard ratio [HR] 10.82, 95% confidence interval [CI] 4.51 to 25.93, p <0.001), Thrombolysis In Myocardial Infarction myocardial flow after percutaneous coronary intervention (HR 0.19, 95% CI 0.07 to 0.50, p = 0.001), and abciximab administration (HR 0.32, 95% CI 0.13 to 0.78, p = 0.01). In conclusion, the results of this multicenter study suggest that selected nonagenarians with acute myocardial infarction benefit from successful primary angioplasty. The treatment does not affect the poor prognosis of patients presenting with cardiogenic shock, but the administration of abciximab seems to have a positive effect on 6-month mortality.
authors.affiliation: Divisione di Cardiologia, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy. gbdanzi@mail.com
authors.forename: Gian Battista
authors.initials: GB
authors.lastname: Danzi
authors.forename: Marco
authors.initials: M
authors.lastname: Centola
authors.forename: Guido A
authors.initials: GA
authors.lastname: Pomidossi
authors.forename: Dario
authors.initials: D
authors.lastname: Consonni
authors.forename: Sara
authors.initials: S
authors.lastname: De Matteis
authors.forename: Amerigo
authors.initials: A
authors.lastname: Stabile
authors.forename: Marco
authors.initials: M
authors.lastname: Sesana
authors.forename: Angelo
authors.initials: A
authors.lastname: Anzuini
authors.forename: Paolo
authors.initials: P
authors.lastname: Sganzerla
authors.forename: Bernardo
authors.initials: B
authors.lastname: Cortese
authors.forename: Angela
authors.initials: A
authors.lastname: Migliorini
authors.forename: David
authors.initials: D
authors.lastname: Antoniucci
mesh_terms: D000077284:Abciximab; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D016001:Confidence Intervals; D003324:Coronary Artery Disease / Q000150:complications; D005260:Female; D016330:Frail Elderly; D006329:Heart Conduction System / Q000503:physiopathology; D017052:Hospital Mortality; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007558:Italy; D008297:Male; D008499:Medical Records; D009203:Myocardial Infarction / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D016017:Odds Ratio; D016016:Proportional Hazards Models; D012044:Regression Analysis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012770:Shock, Cardiogenic / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab